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Abstract 
Purpose: To formulate and prepare controlled release (CR) matrix tablets of tramadol HCl using 
Carbopol 974P and 934 polymers as rate-controlling agents.  
Methods: The tablets were prepared by direct compression method using various drug to polymer (D:P) 
ratios. Co-excipients, including carboxymethylcellulose, starch and/or hydroxypropyl methylcellulose 
were also used to modulate the formulations. Various physical tests and in vitro dissolution studies were 
carried out on the formulations. The dissolution data were subjected to various release models 
Results: As the concentration of the polymer (rate-controlling agent) increased, dissolution rate 
decreased, For the formulation containing Carbopol 974P at D:P ratio of 10:7, drug release decreased 
to 83 % compared with  the release rate of 99 % for the formulation with D:P ratio of 10:3. Kinetic 
analysis indicates that drug release mechanism was anomalous non-Fickian diffusion.  
Conclusion: Both Carbopol 974P and 934 can be used as rate-controlling agents in the formulation of 
tramadol HCl CR tablets. Appropriate selection of drug/polymer ratio can be applied effectively to 
modulate the dissolution rate of the drug.    
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Immediate release dosage forms have negligible 
control on drug release from dosage form that 
generally leads to constantly changing, 
unpredictable sub or supra therapeutic drug 
concentrations in plasma [1]. Controlled release 
(CR) formulations are used to overcome the 
drawbacks of immediate release formulations. 
Matrix system is the most widely used method for 
the development of CR dosage form due to its 
ease of manufacture. Different natural and 
synthetic polymers are used for CR matrix 
systems which have the property to extend the 
release of drug from matrix system [2]. In matrix 
systems, the release of drugs from the 
hydrophilic polymers is controlled by a 
combination of mechanisms such as polymer 
swelling, erosion and diffusion [3]. Carbopols or 
carbomers (hydrophilic polymer) compress very 
well and have strong binding characteristics 
which make them ideal for direct compression 
process. They show compatibility with various 
active ingredients and other excipients [4,5]. 
Carbopol 974P and Carbapol 934 are oral 
pharmaceutical grades of carbomers. Their 
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hydrophilic nature and highly crosslinked 
structure make them suitable candidates for CR 
formulations [6]. 
 
Tramadol hydrochloride, an opoid analgesic used 
in severe acute and chronic pain has a good 
bioavailability and is prescribed 3-4 times a day. 
This frequent dosing schedule cause increased 
incident of side effects, non compliances and 
development of tolerance especially in long term 
used like osteoarthritis, arthritis, post surgical 
pains etc [7]. It can be suggested that there is a 
strong clinical implication of CR  formulation of 
this drug.  
 
The present study has the objective of designing 
a CR matrix system of tramadol HCl, using 
Carbopol 974P and Carbopol 934 as the polymer 






Tramadol HCl (Global Pharma, Islamabad, 
Pakistan), Carbopol 974P NF and Carbopol 934 
(Dow Chemical Co, Midland, USA), sodium 
hydroxide (Merck, Germany), monobasic 
potassium phosphate (Merck, Germany),  lactose 
and magnesium stearate (BDH Chemicals, 
Poole, England), carboxymethylcellulose CMC 
and starch (Velor Pharmaceuticals, Islamabad 
Pakistan) were used. PharmaTest dissolution 
apparatus (D-6312, Hainburg, Austria), single-
punch tablet machine (Erweka AR-400, 
Germany), UV visible spectrophotometer 
(UVIDEC-1601, Shimadzu, Japan), hardness 
tester (Erweka TB-24, Germany) and friability 
tester (Erweka TA3R, Germany were the 
equipment used). 
 
Standard Calibration Curve for Tramadol HCl 
 
The standard regression equation for tramadol 
HCl obtained was y = 5.6801x + 0.0085 with a 
coefficient of regression (R2) of 0.9998. 
   
Drug/polymer compatibility study 
 
Compatibility study was carried out to determine 
compatibility between tramadol HCL (TH) and 
Carbopol 974P and 934 polymers. Briefly, the 
drug and polymer were thoroughly mixed in a 
vertex mixer in D:P of 1:1, and then dissolved in 
phosphate buffer (pH 7.4). Samples were 
collected after 15 min and analysed 
spectrophotometrically at 270 nm for drug 
content. Any colour change was also inspected 
visually. Thereafter, the drug and polymers were 
mixed in the same ratio (1:1) and dissolved in 
water in glass vials and stored at 50 oC for 2 
weeks [8,9]. After two weeks, samples were 
taken from the physical mixtures and again 
analysed visually for any change in colour and 
also analysed spectrophotometericaly for drug 
content. 
 
Formulation and tablet preparation 
 
Tablets of TH were prepared by direct 
compression method. The batch size of each 
formulation was 100 tablets. Table 1 shows the 
composition of the formulations. Lactose was 
used as a filler and magnesium stearate as 
lubricant. All the ingredients, except magnesium 
stearate, were blended geometrically in pestle 
and mortar for 10 min and then passed through 1 
mm aperture sieve thrice for uniform distribution 
of the ingredients. Magnesium stearate was 
added and again passed through the sieve. The 
mixture was compressed into tablets 
(compressing weight, 200 mg) in a single punch 
tablet machine (Erweka AR-400 Germany) fitted 
with 8 mm round concave punches. 
 
Physicochemical characterization of the 
tablets 
 
These tests were carried out according to USP 
[10], as appropriate. Dimensional tests (thickness 
and diameter) were performed with the aid of 
Vernier calliper [11]. Weight variation test was 
performed on 20 tablets from each batch with an 
electronic weighing balance and the mean taken. 
Hardness test was performed with a hardness 
tester (Erweka TB24, Germany) on the 10 tablets 
from each batch and the mean taken. Friability 
test was carried out on 20 tablets using a friability 
tester (Erweka TA3R, Germany) rotating at 25 
rpm for 4 min and the mean loss of weight 
determined. 
 
In vitro dissolution studies 
 
With the aid of Pharmatest dissolution apparatus 
(D-6312, Hainburg), in vitro dissolution studies 
were conducted using USP Method-I. Potassium 
phosphate buffer (900 ml, pH 7.4) was used as 
dissolution medium at 37  ±1 oC and the speed of 
the rotating baskets was 100 rpm. Samples (5 
ml) were taken at various time intervals and 
analysed spectrophotometrically at 270 nm after 
filtering through a 0.45 µ filter. Percent drug 
release was calculated. 
 
Drug release kinetics 
 
By plotting the fraction release verses time, the 
drug release kinetics was determined by fitting 
the data to kinetic models as in Eqs 1 – 5 [12-14] 
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Table 1: Composition of 200 mg tramadol HCl/Carbopol matrix tablets 
 












TH/Carbopol tablets without co-excepients 
F1 10:3 100mg 30 mg 69 mg 1mg  
F2 10:4 100mg 40 mg 59 mg 1mg  
F3 10:5 100mg 50 mg 49 mg 1mg  









F5 10:7 100mg 70 mg 29 mg 1mg  
F6 10:3 100mg 30 mg 69 mg 1mg  
F7 10:4 100mg 40 mg 59 mg 1mg  
F8 10:5 100mg 50 mg 49 mg 1mg  








F10 10:7 100mg 70 mg 29 mg 1mg  
TH-Carbopol Tablets with co-excipients (CMC, HPMC and starch) 
Carbopol 974P F11 10:4 100mg 40 mg 41.3 mg 1mg 17.7mg 
Carbopol 934 F12 10:4 100mg 40 mg 41.3 mg 1mg 17.7mg 
 
Zero order:      W = K1t         (1) 
First order:      In (100 –W) = In100 – K2t        (2) 
Higuchi:      W = K4 t1/2         (3) 
Hixson Crowell: (100 – W)1/3 = 1001/3 – K3t    (4) 
Korsmeyer-Pappas:      Mt / M∞ = K5tn       (5) 
 
where W = the amount of drug release at time, t, 
k1 = the zero-order release rate constant, k2 = the 
first order release rate constant, k3 = a constant 
incorporating the surface volume relationship, k4 
= Higuchi dissolution rate constant, k5 = kinetic 
constant compromising the structural and 
geometric characteristics of the device, n = the 
diffusion exponent for drug release, and Mt /M∞ = 
the fraction of drug release at time, t 
 
Korsmeyer-Peppas equation, which showed the 
best-fit, was selected, with the fractional drug 
release into the dissolution medium shown by Mt 
/ M∞. K is the constant which is the property of 
the drug delivery system, and n is the diffusional 
exponent which shows the drug release 
mechanism, i.e., when n = 0.5, then the drug is 
released from the matrix tablet with a quasi-
Fickian mechanism; when n > 0.5, then 
anomalous, non-Fickian release mechanism 
exists, and when n = 1, then non-Fickian, Case II 
or Zero order release mechanism exists.  
 
Determination of similarity factor (f2) 
 
For comparison of the in vitro dissolution profiles 
of two drug formulations, one being the test drug 
and other the reference standard, Food and Drug 
Agency (FDA) and Committee for Proprietary 
Medicinal Products (CPMP) adopted similarity 
factor (f2). Its value ranges from 50 - 100. Values 
< 50 show dissimilarity while values > 50 indicate 
similarity in in vitro release drug profile [16,17]. f2 
was determined as in Eq 6. 
f2 = 50Log {[1+1/n Wt ∑nt=1   (Rt-Tt) 2] -0.5 ×100} 
 (6) 
where n is pull point, Wt is an optional weight 
factor, Rt the reference release profile at point, t, 




For statistical significance, one-way ANOVA at p 
< 0.05 was conducted for the release profile 




No change in colour of the physical mixtures of 
the drug and polymers were observed even after 
two weeks of storage. No change in drug content 
was also observed. The drug content of the 
drug/carbopol 974P was 99.12 ± 1.17 and 99.32 
± 1.93 before and after 2 weeks, respectively and 
for the physical mixture containing carbopol 934, 
it was 100.23 ±1.89 and 100.32 ±1.11 
respectively.  Compatibility results showed that 
there was no incompatibility between the drug 
and the polymers which means the polymers can 
be used as matrix materials for the preparation of 




Mean tablet was in the range 198 - 203 ± 0.15 
mg, indicating good uniformity of weight [11]. 
Tablet hardness was 6.60 ± 0.10 to 7.80 ± 0.08 
kg/cm2 which is within the recommended USP 
range of 5 – 10 kg/cm2. Thickness and diameter 
were 2.60 ± 0.05 and 8.00 ± 0.07mm,  
respectively which are within the acceptable USP 
range of 2 - 4mm and 4 – 13 mm, respectively. 
Desirable friability limit is < 0.8 % while the 
tablets obtained exhibited friability in the range of 
0.22 ± 0.08 to 0.32 ± 0.04 %.  
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              Table 2: Hardness and friability of tramadol formulations 
 
Polymer Formulation Hardness (kg/cm2) Friability (%) 
F2 7.23 ± 0.11 0.22 ± 0.08 
F3 6.60 ± 0.10 0.28 ± 0.10 
Carbopol 974P 
F4 6.94 ± 0.07 0.32 ± 0.04 
F7 7.80 ± 0.08 0.25 ± 0.03 
F8 7.45 ± 0.15 0.30 ± 0.03 
Carbopol  934 
F9 6.99 ± 0.05 0.23 ± 0.09 
 
Table 3: Kinetic release data for selected formulations 
 










F2 10:4 0.932 0.945 0.954 0.932 0.976 






F4 10:6 0.921 0.944 9.935 0.956 0.988 
F7 10:4 0.934 0.945 0.967 0.930 0.977 







F9 10:6 0.922 0.942 0.964 0.952 0.983 
 
In vitro drug release  
 
Drug release data are shown in Figs 1 and 2. As 
the proportion of polymer increased drug release 
delayed.  
 
Fig 1: Drug release tramadol tablets containing Carbapol 
974P. Key: ■ = F1, ▲ = F2, □ = F3,  x = F4, anf ● =  F5, 
compared standard (◊); n = 3 
 
 
Fig 2: Drug release tramadol tablets containing 
Carbapol 974P. Key: ■ = F5, ▲ = F6, □ = F7,  x = F8, 
anf ● =  F9, compared standard (◊); n = 3 
 
Influence of co-excipients 
 
Figure 3 shows the effect of starch, CMC and 
HPMC, used as co-excepeints, on tramdol CR 
tablets containing either Carbopol 974P or 934. 




Fig 3: Drug release profiles of tramadol tablets. Key: 
Carbopol 974P = ▬, Carbopol 934 = + 
▲= HPMC + 974P, ∆ = HPMC + 934, ■ = starch + 
974P, □ = starch + 934, ● = CMC + 974P,  
○ = CMC + 934 (mean n = 3)  
 
Release kinetics  
 
The results are shown in Table 2. The n value for 
formulations F2, F3 and F4 were 0.976, 0.987 
and 0.988 respectively and those for F4, F5 and 
F6 were 0.977, 0.984 and 0.983 respectively 
Korsmeyer-Peppas kinetic model showed the 
best fitting for the formulations [17].  
Similarity factor  
 
The similarity factor (f2) for F2, F3 and F4 was 
35.9, 34.7 and 31.8, respectively, while for 
formulations F7, F8 and F9, it was 36.8, 33.5, 
and 31.5, respectively. Thus, the release drug 
profiles of the test formulations were different 




All the physicochemical data obtained were 
within acceptable official ranges, and hence the 
tablets can be further investigated for tramadol 
release.  
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As the concentration of Carbopol increased, less 
drug was released from the polymer. This may 
be due to hydration of the polymer matrix as it it 
swells on contact with water and thus closes up 
the microspores in the swollen tablet, causing a 
decrease in drug release from the tablet [5]. 
Furthermore, increase in the amount of the 
carbomer resulted not only in a reduction of drug 
release rate but linearization of the drug release 
curve, leading to a shift towards a swelling-
controlled mechanism.  
 
An additional factor may be a reduction in the 
region of low microviscosity in the swollen tablet. 
The swelling of a tablet due to polymer hydration 
results in a rapid decrease in its glass transition 
temperature (Tg). Microscopically, there is a 
relaxation of the polymer chains due to stresses 
introduced by the presence of the dissolution 
medium which results in an increase in the radius 
of gyration and end-to-end distances of the 
polymer chains [5,18]. The resulting increase in 
the molecular volume of the hydrated polymer 
reduces free volume due to the presence of the 
microspores. This effect may manifest as a shift 
in drug release mechanism [19-21]. 
 
In tablets containing co-excipients, the drug was 
released from the polymer in a shorter time and 
nearly maximum release was shown after 12 h. 
Starch is insoluble in water. Insoluble solids may 
produce non-uniformity in the polymeric 
membrane around the drug, causing imperfection 
in the membrane, leading to quick release of 
drug from the tablets. Starch is water swellable 
and could have caused rupture of the polymeric 
membrane, and increase in drug release rates. 
Our findings in respect of the influence of starch 
are in agreement with those of Khan & Zhu [5] 
and Shefaat et al [22].  
 
CMC, a water soluble polymer, also enhanced 
the release rate of tramadol HCl from the tablets 
and thus confirms the findings of Khan & Zhu 
[23] and Shefaat et al [22] that water-soluble co-
excipients can create osmotic forces that may 
break up membranous barriers, resulting in 
higher release rate. The effect of inclusion of 
HPMC, also a water soluble polymer, was similar 
to that of CMC, and the same mechanism 
applies [5,22].  
 
The value of the diffusion coefficient (n) in the 
Korsmeyer-Peppas model being > 0.5 for all the 
CR formulations, indicates that drug transport 
mechanism was anomalous, non-Fickian 
diffusion. The f2 data further lend support to the 





The tablets developed showed good 
physicochemical properties and demonstrated 
satisfactory controlled drug release. Thus, 
Carbopol 974P and 934 are suitable drug release 
rate-controlling polymers for tramadol and 
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